Suchen
Neuronetics Inc
STIMZur Watchlist hinzufügen
1.410USD
+0.060+4.44%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
98.11MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Neuronetics Inc Unternehmen
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Neuronetics Inc Informationen
BörsenkürzelSTIM
Name des UnternehmensNeuronetics Inc
IPO-datumJun 28, 2018
CEOMr. Keith J. Sullivan
Anzahl der mitarbeiter716
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
Addresse3222 Phoenixville Pike
StadtMALVERN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19355
Telefon18776007555
Websitehttps://neurostar.com/neuronetics/
BörsenkürzelSTIM
IPO-datumJun 28, 2018
CEOMr. Keith J. Sullivan
Führungskräfte von Neuronetics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.06M
+1.46%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
625.02K
+5.80%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
340.45K
+8.81%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
190.35K
+15.76%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
170.89K
+17.56%
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.06M
+1.46%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
828.78K
+1.03%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
625.02K
+5.80%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
340.45K
+8.81%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
190.35K
+15.76%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
170.89K
+17.56%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Neuronetics Inc?
Die fünf größten Anteilseigner von Neuronetics Inc sind: Mr. Sasha Cucuz
Wie viele Institutionen halten Anteile an Neuronetics Inc (STIM)?
Mit Stand vom 2026Q1 halten 236 Institutionen Anteile an Neuronetics Inc, mit einem Gesamtmarktwert von etwa 47.87M, was 68.80% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -7188276.00 gestiegen.
Was ist die größte Einnahmequelle von Neuronetics Inc?
Am 2026Q1 erzielte das Geschäft mit Clinic revenue für Neuronetics Inc den höchsten Umsatz in Höhe von 86.98M, was 58.31% des Gesamtumsatzes entspricht.